An immunomodulatory peptide, Og-CATH, and its applications

By isolating and identifying the immunomodulatory peptide Og-CATH from the skin of the fingerless disc-shaped frog, the problem of antibiotic resistance to bacteria has been solved, providing an effective immunomodulatory therapy that significantly improves the protective effect against drug-resistant bacterial infections.

CN116496376BActive Publication Date: 2026-11-17KUNMING MEDICAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310490782.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-04
Publication Date
2026-11-17
Estimated Expiration
2043-05-04

AI Technical Summary

Technical Problem

Current antibiotic treatments for bacterial infections face the problem of drug resistance, especially infections caused by methicillin-resistant Staphylococcus aureus and carbapenem-resistant Escherichia coli, for which there is a lack of effective immunomodulatory therapies.

Method used

A unique immunomodulatory peptide, Og-CATH, was isolated and identified from the skin of the fingerless frog. It has anti-drug-resistant bacterial infection activity and can be prepared into an antibacterial drug for treatment by inducing immune cell chemotaxis and enhancing innate immune response.

Benefits of technology

Og-CATH significantly enhanced the innate immune response in mice, significantly improved the protective effect against methicillin-resistant Staphylococcus aureus and carbapenem-resistant Escherichia coli, and increased the survival rate of mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116496376B_ABST
    Figure CN116496376B_ABST
Patent Text Reader

Abstract

This invention discloses an immunomodulatory peptide Og-CATH and its applications, belonging to the biomedical field. The immunomodulatory peptide Og-CATH is a linear, straight-chain polypeptide encoded by the defense peptide gene of the Chinese amphibian endemic species, *Rhizoctonia solani*, with a molecular weight of 3078.59 Daltons and an isoelectric point of 12.78. Its amino acid sequence is shown in SEQ ID NO:2. The gene encoding the precursor of the *Rhizoctonia solani* immunomodulatory peptide Og-CATH consists of 645 nucleotide sequences, as shown in SEQ ID NO:1; nucleotides 367-453 are the encoding gene for the mature *Rhizoctonia solani* immunomodulatory peptide Og-CATH. The application of the *Rhizoctonia solani* immunomodulatory peptide Og-CATH in the preparation of drugs against methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Escherichia coli (CRE) infections is discussed. The beneficial effects include a strong regulatory effect on the host's major immune cells, significantly resisting MRSA and CCRE infections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to an immunomodulatory peptide Og-CATH and its applications. Background Technology

[0002] Bacterial infections can cause complications such as bacteremia and sepsis, inducing septic shock and organ failure, seriously threatening human life and health. Currently, antibiotic therapy remains the primary treatment for bacterial infections. However, due to the excessive or inappropriate use of antibiotics in anti-infective treatment and livestock farming, a large number of bacteria have developed drug resistance, such as methicillin-resistant Staphylococcus aureus. Staphylococcus aureus MRSA), carbapenem-resistant Escherichia coli Escherichia coli Antimicrobial resistance has become a pressing global public health problem. Immunomodulatory therapy refers to disease treatment methods that induce, enhance, or suppress immune responses. Compared with traditional antibiotics, immunotherapy targets the body's innate immune system, has a broader range of effects, and is less likely to induce resistance. Therefore, immunomodulatory therapy is a promising new therapy for combating drug-resistant bacterial infections.

[0003] Amphibians, as a transitional type between aquatic and terrestrial vertebrates, inhabit complex and diverse environments. Their skin is bare and smooth, capable of secreting a large number of bioactive molecules to defend against biotic and abiotic attacks from the environment. These bioactive molecules participate extensively in various physiological activities of the body and possess various pharmacological activities, such as antimicrobial, antitumor, antioxidant, and wound repair effects. Neutrophils and macrophages are the two most potent phagocytic and bactericidal cell types in the innate immune system. Some bioactive peptides can also indirectly resist microbial invasion by inducing macrophages and neutrophils to chemotactically approach the site of infection. These bioactive peptides with immunomodulatory functions are also called immunomodulatory peptides. According to domestic and international literature, different immunomodulatory peptides have been isolated from various organisms. *Dactylophora indica* (a type of frog) Odorranagrahami The *Stachys spp.* belongs to the genus *Stachys* in the family Ranidae of the order Anura, and is endemic to China. Current research on the active ingredients in the skin of *Stachys spp.* mainly focuses on their direct antibacterial and antitumor activities, while the immunomodulatory peptides in its skin and their anti-infective effects have not yet been reported. Summary of the Invention

[0004] The first objective of this invention is to provide an immunomodulatory peptide Og-CATH; the second objective is to provide applications of the aforementioned immunomodulatory peptide Og-CATH.

[0005] The first objective of this invention is achieved as follows: the nucleotide sequence of the immunomodulatory peptide Og-CATH is shown in the sequence listing SEQ ID NO: 1.

[0006] The immunomodulatory peptide Og-CATH described in this invention has anti-methicillin-resistant Staphylococcus aureus and carbapenem-resistant Escherichia coli infection activity.

[0007] The immunomodulatory peptide Og-CATH described in this invention is a linear polypeptide encoded by the defense peptide gene of the Chinese amphibian endemic species, *Rana ventricosa*, with a molecular weight of 3078.59 Daltons and an isoelectric point of 12.78. The gene encoding this immunomodulatory peptide precursor consists of 645 nucleotides, with the following sequence from the 5' to the 3' end: [Sequence details omitted]. Nucleotides 367-453 encode the mature immunomodulatory peptide Og-CATH.

[0008] The beneficial effects of this invention are as follows: It provides a novel immunomodulatory peptide, Og-CATH, from the fingerless frog that has the effect of resisting infection by methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Escherichia coli (CRE). This fingerless frog immunomodulatory peptide has significant antibacterial infection activity and can significantly protect mice from infection by MRSA and CCRE. It can be used in the preparation of therapeutic drugs against MRSA and CCRE infections. Attached Figure Description

[0009] Figure 1 This is a schematic diagram illustrating the extremely strong immunotactic activity of the immunomodulatory peptide Og-CATH of the present invention. Mice were injected intraperitoneally with Og-CATH (10 mg / kg). Peritoneal lavage fluid was collected at 6, 12, 24 and 48 h after injection. Flow cytometry was used to analyze the chemotactic effect of Og-CATH on monocytes / macrophages and neutrophils in mice. Among them, (A) gated images of monocytes / macrophages and neutrophils by flow cytometry; (B) statistical graphs of monocytes / macrophages and neutrophils. ns, **p<0.01, ***p<0.001; Figure 2 This is a schematic diagram illustrating the extremely strong anti-methicillin-resistant Staphylococcus aureus and carbapenem-resistant Escherichia coli infection effects of the immunomodulatory peptide Og-CATH of the present invention. Intraperitoneal injection of Og-CATH 4 hours before or 0.5 hours after bacterial infection improves the survival rate of mice infected with lethal doses of bacteria. Among them, (A) mice were infected with a lethal dose of MRSA; and (B) mice were infected with a lethal dose of CREC. Detailed Implementation

[0010] The present invention will be further described below with reference to embodiments and accompanying drawings, but this does not limit the present invention in any way. Any modifications or substitutions made based on the teachings of the present invention shall fall within the protection scope of the present invention.

[0011] The nucleotide sequence of the immunomodulatory peptide Og-CATH described in this invention is shown in SEQ ID NO: 1 of the sequence listing.

[0012] The amino acid sequence encoded by the immunomodulatory peptide Og-CATH is shown in SEQ ID NO: 2.

[0013] The application of the immunomodulatory peptide Og-CATH described in this invention is its use in the preparation of antibacterial drugs.

[0014] The invention will be further illustrated below with specific implementation examples: Example 1 Gene cloning of the immunomodulatory peptide Og-CATH (1) Total RNA extraction from the skin of the fingerless frog: Rinse the skin on the back of the fingerless disc-shaped frog with deionized water, then flash-freeze in liquid nitrogen for 10 hours. Take 100 mg of skin tissue, add 1 ml of Trizol solution, and homogenize in a 20 ml glass homogenizer for 30 minutes. Add an equal volume of phenol / chloroform solution, mix vigorously, incubate at room temperature for 10 minutes, centrifuge at 12000 rpm for 10 minutes at 4°C, and discard the precipitate. Add an equal volume of isopropanol to the supernatant, incubate at room temperature for 10 minutes, centrifuge at 12000 rpm for 10 minutes at 4°C, wash the precipitate once with 75% ethanol, air dry, and the precipitate at the bottom of the tube is the total RNA from the skin.

[0015] (2) Construction of cDNA library from the skin of the fingerless frog: Using CLONTECH's Creator TM SMART TM The cDNA Library Construction Kit is a plasmid-cDNA library construction kit. Follow the instructions in the manual for specific operation.

[0016] The first-chain synthesis utilizes the CDS Ⅲ / 3' Primer provided in the kit. 5'-ATTCTAGAGGCCGAGGCGGCCGACATG (30) N-1N-3' (N=A,C,G or T;N-1=A,G or C) and SMART TM IV. oligo nucleotide: 5'-AAGCAGTGGTATCAACGCAGAGTGGCCATTACGGCCGGG-3'. The second chain was synthesized using CDS Ⅲ / 3' Primer provided in the kit. 5'-ATTCTAGAGGCCGAGGCGGCCGACATG-3' and 5'primer 5'-AAGCAGTGGTATCAACGCAGAGT-3'. The reverse transcriptase used for first-strand synthesis and the high-fidelity polymerase used for second-strand synthesis were provided by the kit. The cDNA double-stranded DNA was stored at -80°C after synthesis.

[0017] (3) Screening of Og-CATH gene clones for immunomodulatory peptide: Degenerate primers were designed based on the conserved region of cathelicidin from published amphibian sources: 5'-(A / T)(C / G)C(A / G)CAG(A / G)(C / T)CTTCACCTCC-3'. These primers, along with the 5' PCR primer from the library preparation kit: 5'-AAGCAGTGGTATCAACGCAGAGT-3', were used. PCR amplification was performed using second-strand cDNA from the skin of the fingerless frog (Rana spp.) as a template. The amplification process consisted of 35 cycles: 94°C pre-denaturation for 2 min, 94°C denaturation for 10 s, 50°C annealing for 30 s, and 72°C extension for 40 s. The PCR products were verified by agarose gel electrophoresis and then sent to a sequencing company for sequencing.

[0018] Based on the 5' end sequence obtained from sequencing, primer 5'-CCATGAGGAGCTGGTGGCTGT-3' was designed and used in conjunction with the 3' PCR primer 5'-ATTCTAGAGGCCGAGGCGGCCG-3' from the library preparation kit for PCR amplification under the same conditions as above. After amplification, the target fragment was recovered using a DNA gel extraction kit, and the band size was verified by gel electrophoresis. The gel-extracted product was ligated overnight with the pMD18-T vector and transformed into *E. coli* DH5α competent cells prepared using the calcium chloride method. The next day, single clones were picked for colony PCR, and positive clones were screened for inoculation and plasmid extraction. Subsequently, the plasmid fragment size was verified by agarose gel electrophoresis, and plasmids corresponding to the correct band size were sequenced.

[0019] (4) Sequence determination of the immunomodulatory peptide Og-CATH gene: Plasmid DNA was extracted and its nucleotide sequence was determined using the dideoxy sequencing method. The instrument used was an Applied Biosystems 373A fully automated nucleotide sequencer, and the sequencing primers were BcaBEST. TM Sequencing Primer RV-M and BcaBEST TM Sequencing Primer M13-47, BcaBEST TM Sequencing Primer RV-M sequence: 5`GAGCGGATAACAATTTCACACAGG 3', BcaBEST TM Sequencing Primer M13-47: 5'CGCCAGGGTTTTCCCAGTCACGAC 3'.

[0020] Gene sequencing results showed that the gene encoding the precursor of the immunomodulatory peptide from the fingerless frog (Rhizophora spp.) consists of 645 nucleotides (SEQ ID NO: 1) (GenBank Accession Number: OQ870535), with the following sequence from the 5' end to the 3' end: [Sequence details omitted]. Nucleotides 367-453 encode the mature fingerless frog immunomodulatory peptide Og-CATH.

[0021] Example 2 Chemical synthesis method of immunomodulatory peptide Og-CATH (1) Synthesized using an automated peptide synthesizer (433A, Applied Biosystems, USA) Buga The complete amino acid sequence of CATH was determined by high-performance liquid chromatography (HPLC) (Waters, USA). 18The synthesized sample was purified by reverse-phase column chromatography desalting. (2) The molecular weight of the synthesized sample was determined by matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF). (3) The purity of the synthesized sample was identified by high-performance liquid chromatography (HPLC). The molecular weight of the chemically synthesized peptide was determined to be 3078.59 Da by MALDI-TOF, and the isoelectric point of the synthesized peptide was determined to be 12.78 by isoelectric focusing electrophoresis. The purity of the synthesized sample was determined to be >95% by HPLC. The amino acid sequence structure of the synthesized Og-CATH was confirmed to be consistent with that of natural Og-CATH by an automated amino acid sequencer.

[0022] Example 3 Pharmacological activity of the immunomodulatory peptide Og-CATH (1) Chemotaxis of the immunomodulatory peptide Og-CATH on major immune cells (macrophages and neutrophils) in mice Male C57BL / 6 mice were intraperitoneally injected with Og-CATH (10 mg / kg) alone, with an equal volume of PBS used as a negative control. At 6, 12, 24, and 48 h post-injection, the peritoneal cavity was irrigated with PBS (5 mL), and the irrigated fluid was collected. Cells were obtained from the peritoneal cavity by centrifugation at 1500 rpm for 10 min. Cells were stained with PE / F4 / 80 (monocytes / macrophages) and FITC / Ly-6G / Ly-6C (Gr-1, neutrophils), and flow cytometry was used to analyze the chemotactic effect of Og-CATH on monocytes / macrophages and neutrophils in mice.

[0023] The results are as follows Figure 1 As shown, a concentration of 10 mg / kg of Og-CATH significantly increased the number of monocytes / macrophages and neutrophils in the peritoneal cavity of mice. This indicates that Og-CATH has a chemotactic effect on innate immune cells (monocytes / macrophages and neutrophils) in mice.

[0024] (2) Application of Og-CATH, an immunomodulatory peptide from the fingerless frog, in the preparation of antibacterial infection treatment drugs. Male C57B / L mice were randomly divided into a sham-operated group (negative control) and a bacterial infection model group (intraperitoneal injection of G). + Drug-resistant bacteria MRSA and G - Drug-resistant bacteria (CREC), Og-CATH treatment group and human cathelicidin LL-37 treatment group (positive control). G + Drug-resistant bacteria MRSA and G - The dosage for intraperitoneal infection caused by drug-resistant CREC is 1.5 x 10⁻⁶. 8CFU / mouse, normal control group, and bacterial infection model group were intraperitoneally injected with PBS solution 4 hours before or 0.5 hours after bacterial infection; Og-CATH group and LL-37 positive control group were intraperitoneally injected with 200 μL each of immunomodulatory peptides Og-CATH and LL-37 (both at a concentration of 10 mg / kg) dissolved in PBS solution 4 hours before or 0.5 hours after bacterial infection. Survival rates of mice were recorded for 7 consecutive days.

[0025] The results are as follows Figure 2 As shown: Mice in the MRSA and CREC infection model groups all died on the third and second days, respectively. However, after intraperitoneal injection of the immunomodulatory peptide Og-CATH 4 hours before bacterial infection, G... + Drug-resistant bacteria MRSA and G - The survival rates of mice infected with drug-resistant CREC reached 50% and 33.33%, respectively; after intraperitoneal injection of the immunomodulatory peptide Og-CATH 0.5 h after bacterial infection, G... + Drug-resistant bacteria MRSA and G - The survival rates of mice infected with drug-resistant CREC reached 83.33% and 66.66%, respectively. This indicates that the immunomodulatory peptide Og-CATH has strong anti-MRSA and anti-CREC infection effects, and its anti-infective effect is stronger than that of LL-37 (see details). Figure 2 ).

[0026] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. An immunomodulatory peptide Og-CATH, characterized in that... The amino acid sequence of the immunomodulatory peptide Og-CATH is shown in SEQ ID NO:

2.

2. The application of the immunomodulatory peptide Og-CATH according to claim 1, characterized in that... The application of the immunomodulatory peptide Og-CATH in the preparation of drugs against methicillin-resistant Staphylococcus aureus and carbapenem-resistant Escherichia coli infections.

Citation Information

Patent Citations

  • R. grahami rnmunoregulating polypeptide, gene and variant and its application in medicine production

    CN101037473A

  • PSM peptides as vaccine targets against methicillin-resistant staphylococcus aureus

    WO2008154101A1